OBJECTIVES: This analysis sought to investigate the waitlist and post-transplant outcomes of individuals bridged to transplantation by using temporary percutaneous endovascular mechanical circulatory support (tMCS) through a status 2 designation (cardiogenic shock and exception). BACKGROUND: The 2018 donor heart allocation policy change granted a status 2 designation to patients supported with tMCS. METHODS: Adult patients in the United Network for Organ Sharing registry after October 18, 2018 who received a status 2 designation for tMCS were included and grouped by their status 2 criteria: cardiogenic shock with hemodynamic criteria (CS-HD), cardiogenic shock without hemodynamic criteria before tMCS (CS-woHD), and exception. Baseline characteristics, waitlist events (death and delisting), and post-transplant outcomes were compared. RESULTS: A total of 2,279 patients met inclusion criteria: 68.6% (n = 1,564) with CS-HD, 3.2% (n = 73) with CS-woHD, and 28.2% (n = 642) with exceptions. A total of 64.2% of patients underwent heart transplantation within 14 days of status 2 listing or upgrade, and 1.9% died or were delisted for worsening clinical condition. Among the 35.8% who did not undergo transplantation following 14 days, only 2.8% went on to receive a left ventricular assist device (LVAD). The 30-day transplantation likelihood was similar among groups: 80.1% for the CS-HD group vs 79.7% for the exception group vs 73.3% for the CS-woHD group; P = 0.31. However, patients who met criteria for CS-woHD had 2.3-fold greater risk of death or delisting (95% CI: 1.10-4.75; P = 0.03) compared with CS-HD patients after multivariable adjustment. Pre-tMCS hemodynamics were not associated with adverse waitlist events. CONCLUSIONS: The use of tMCS is an efficient, safe, and effective strategy as a bridge to transplantation; however, patients with CS-woHD may represent a high-risk cohort. Transition to a durable LVAD was a rare event in this group.
OBJECTIVES: This analysis sought to investigate the waitlist and post-transplant outcomes of individuals bridged to transplantation by using temporary percutaneous endovascular mechanical circulatory support (tMCS) through a status 2 designation (cardiogenic shock and exception). BACKGROUND: The 2018 donor heart allocation policy change granted a status 2 designation to patients supported with tMCS. METHODS: Adult patients in the United Network for Organ Sharing registry after October 18, 2018 who received a status 2 designation for tMCS were included and grouped by their status 2 criteria: cardiogenic shock with hemodynamic criteria (CS-HD), cardiogenic shock without hemodynamic criteria before tMCS (CS-woHD), and exception. Baseline characteristics, waitlist events (death and delisting), and post-transplant outcomes were compared. RESULTS: A total of 2,279 patients met inclusion criteria: 68.6% (n = 1,564) with CS-HD, 3.2% (n = 73) with CS-woHD, and 28.2% (n = 642) with exceptions. A total of 64.2% of patients underwent heart transplantation within 14 days of status 2 listing or upgrade, and 1.9% died or were delisted for worsening clinical condition. Among the 35.8% who did not undergo transplantation following 14 days, only 2.8% went on to receive a left ventricular assist device (LVAD). The 30-day transplantation likelihood was similar among groups: 80.1% for the CS-HD group vs 79.7% for the exception group vs 73.3% for the CS-woHD group; P = 0.31. However, patients who met criteria for CS-woHD had 2.3-fold greater risk of death or delisting (95% CI: 1.10-4.75; P = 0.03) compared with CS-HD patients after multivariable adjustment. Pre-tMCS hemodynamics were not associated with adverse waitlist events. CONCLUSIONS: The use of tMCS is an efficient, safe, and effective strategy as a bridge to transplantation; however, patients with CS-woHD may represent a high-risk cohort. Transition to a durable LVAD was a rare event in this group.
Authors: David A Baran; Cindy L Grines; Steven Bailey; Daniel Burkhoff; Shelley A Hall; Timothy D Henry; Steven M Hollenberg; Navin K Kapur; William O'Neill; Joseph P Ornato; Kelly Stelling; Holger Thiele; Sean van Diepen; Srihari S Naidu Journal: Catheter Cardiovasc Interv Date: 2019-05-19 Impact factor: 2.692
Authors: Rebecca R Goff; Kimberly Uccellini; Kelsi Lindblad; Shelley Hall; Ryan Davies; Maryjane Farr; Scott Silvestry; Joseph G Rogers Journal: Am J Transplant Date: 2020-06-14 Impact factor: 8.086
Authors: M Colvin; J M Smith; Y Ahn; M A Skeans; E Messick; R Goff; K Bradbrook; J Foutz; A K Israni; J J Snyder; B L Kasiske Journal: Am J Transplant Date: 2021-02 Impact factor: 8.086
Authors: Kiran K Khush; Wida S Cherikh; Daniel C Chambers; Michael O Harhay; Don Hayes; Eileen Hsich; Bruno Meiser; Luciano Potena; Amanda Robinson; Joseph W Rossano; Aparna Sadavarte; Tajinder P Singh; Andreas Zuckermann; Josef Stehlik Journal: J Heart Lung Transplant Date: 2019-08-10 Impact factor: 10.247
Authors: Arman Kilic; Michael A Mathier; Gavin W Hickey; Ibrahim Sultan; Victor O Morell; Suresh R Mulukutla; Mary E Keebler Journal: JAMA Cardiol Date: 2021-02-01 Impact factor: 14.676
Authors: Veli K Topkara; Kevin J Clerkin; Justin A Fried; Jan Griffin; Jayant Raikhelkar; Sun Hi Lee; Farhana Latif; Marlena Habal; Evelyn Horn; Maryjane A Farr; Koji Takada; Yoshifumi Naka; Ulrich P Jorde; Gabriel Sayer; Nir Uriel Journal: Circ Heart Fail Date: 2021-05-28 Impact factor: 10.447